Investigating how a protein can help reduce heart damage from a genetic mutation
Chip phosphorylation stimulates the degradation of mutant transthyretin to attenuate cardiac amyloidosis
This study is looking at a heart condition called cardiac amyloidosis, which happens when a protein builds up in the heart, and it's testing a new way to help break down these harmful proteins using a special enzyme, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10882087 on NIH RePORTER |
What this research studies
This research focuses on cardiac amyloidosis caused by a mutation in the transthyretin protein, which leads to harmful protein aggregation in the heart. The study aims to enhance the degradation of these aggregates using a protein kinase called PKG, which has been shown to activate a key protein, Chip, that helps manage protein levels in heart cells. By creating advanced models and utilizing human tissue samples, the research seeks to uncover the mechanisms of this condition and develop potential therapeutic strategies. Patients may benefit from insights that could lead to new treatments for this serious heart disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cardiac amyloidosis due to transthyretin mutations.
Not a fit: Patients without transthyretin-related cardiac amyloidosis or those with other unrelated cardiac conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart function and quality of life for patients with cardiac amyloidosis.
How similar studies have performed: Previous research has shown promise in targeting protein degradation pathways for similar conditions, indicating potential for success in this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Ranek, Mark John — Johns Hopkins University
- Study coordinator: Ranek, Mark John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.